Bank of America Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $93.00

PTC Therapeutics (NASDAQ:PTCT) had its price target cut by research analysts at Bank of America from $97.00 to $93.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s price target points to a potential upside of 31.62% from the stock’s current price.

PTCT has been the subject of several other reports. TD Cowen restated a “hold” rating on shares of PTC Therapeutics in a research note on Thursday, January 29th. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada downgraded shares of PTC Therapeutics from an “outperform” rating to a “sector perform” rating and upped their price target for the company from $82.00 to $91.00 in a research note on Monday, December 1st. The Goldman Sachs Group raised their price target on shares of PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a research report on Wednesday, November 5th. Finally, Jefferies Financial Group boosted their price objective on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Ten analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $80.73.

PTC Therapeutics Stock Performance

Shares of PTCT opened at $70.66 on Friday. The firm has a market cap of $5.67 billion, a P/E ratio of 9.13 and a beta of 0.48. PTC Therapeutics has a 52 week low of $35.95 and a 52 week high of $87.50. The firm’s 50-day simple moving average is $74.91 and its 200 day simple moving average is $68.02.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 373.67% and a net margin of 39.44%.The company had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. During the same quarter last year, the business earned ($0.85) earnings per share. The company’s revenue was down 22.7% on a year-over-year basis. As a group, equities analysts forecast that PTC Therapeutics will post -4.52 earnings per share for the current year.

Insider Activity

In other PTC Therapeutics news, CAO Christine Marie Utter sold 2,494 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total value of $172,983.84. Following the transaction, the chief accounting officer directly owned 70,199 shares of the company’s stock, valued at $4,869,002.64. This trade represents a 3.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Pauwels sold 3,019 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total transaction of $209,397.84. Following the sale, the insider directly owned 77,122 shares of the company’s stock, valued at approximately $5,349,181.92. This trade represents a 3.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 298,246 shares of company stock valued at $23,393,870. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On PTC Therapeutics

A number of institutional investors have recently modified their holdings of PTCT. Ameritas Investment Partners Inc. increased its position in PTC Therapeutics by 3.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,936 shares of the biopharmaceutical company’s stock valued at $388,000 after acquiring an additional 231 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 236 shares during the last quarter. Allworth Financial LP grew its stake in shares of PTC Therapeutics by 63.8% in the fourth quarter. Allworth Financial LP now owns 634 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 247 shares during the last quarter. Optiver Holding B.V. increased its holdings in PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 249 shares during the period. Finally, Measured Wealth Private Client Group LLC raised its position in PTC Therapeutics by 5.6% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 4,963 shares of the biopharmaceutical company’s stock worth $377,000 after purchasing an additional 265 shares during the last quarter.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.